• Financial guidance: Mankind Pharma is targeting double-digit top-line growth to outperform the Indian Pharma Market (IPM), while projecting full-year EBITDA margins between 25.5% and 26.5% compared to 25.4% achieved in FY26.
• Chronic portfolio focus: The chronic segment accounted for approximately 39% of sales in FY26 and reached 40% in the final quarter, serving as a primary driver for consistent future revenue growth.
• GLP-1 drug strategy: The company is taking a contrarian approach to the GLP-1 weight-loss market by staying on the sidelines initially and planning an entry that bundles the drug with vitamins and protein therapies.
• BSV growth outlook: High double-digit growth is expected from the BSV acquisition, supported by robust domestic performance and operational restructuring in its international business.
• Export business target: Exports contribute 14% of top-line revenue, where the company selectively targets double-digit growth by focusing on complex, high-margin products rather than vanilla formulations.